diagnost tool
largest clinic laboratori us
focus routin gene-bas esoter test
quest weather storm fy outlook intact
reiter non-consensu buy rate pt
despit sever weather compani clarifi us post-cal
year-over-year basi vs state gross impact call deliv
ep beat rel our/street expect impress reiter full
year guid encourag see activ hospit re-
think lab strategi help meet exceed goal drive point
revenu growth year expect acceler pace
benefit easier comparison hope major hurrican
like last year reiter buy rate pt adj ep
ep beat adj ep y/i beat rev
beat came street
consensu larg adjust sever weather model
impact rev/volum attribut weather impact call
y/i basi revenue /req posit surpris well our/street
volum volum grew view solid
sinc sever weather number day quarter drag vs
weather y/i less day due time new
year day fall monday year vs sunday prior year organ volum
flat due fewer day pl agreement count
organ anniversari volum ad volum growth
recal complet acquisit ad point revenu growth
fact contribut point revenu growth
reiter guid add point revenu growth
aet contract quest continu product convers health
plan includ hope get back network commentari
limit prefer in-network contract aet contract sever
year howev aet could talk lh earli choos seem
approach negoti may choos go non-exclus includ
lh next year would net posit
tax reform quest tax rate nice prior year
reiter tax rate guid
tax reinvest quest initi tax save reinvest busi
impact oper margin expect invest save
tax back busi technolog improv enhanc
user experi consum initi etc tax save drop
bottom line plan reinvest organ growth busi
expect invest inorgan acquir hospit outreach lab
guide/model reiter revenue guid y/i
adj ep rais adj ep rais
rev maintain revenue growth
target respect model adj ep
respect exclud acquisit announc typic
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin april et
date time product april et
price target use multipl adj ep estim
laboratori corpor america hold lh
pt use multipl adj ep estim
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
diagnost tool
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
